Fidelity Disruptive Medicine ETF (NASDAQ:FMED) Sees Large Decrease in Short Interest

Fidelity Disruptive Medicine ETF (NASDAQ:FMED) was the target of a large decline in short interest in September. As of September 15th, there was short interest totaling 4,130 shares, a decline of 36.9% from the August 31st total of 6,541 shares. Based on an average daily trading volume, of 5,757 shares, the short-interest ratio is presently 0.7 days. Currently, 0.3% of the company’s stock are sold short.

Hedge Funds Weigh In On Fidelity Disruptive Medicine ETF

A hedge fund recently bought a new position in Fidelity Disruptive Medicine ETF stock. Citadel Advisors LLC acquired a new stake in shares of Fidelity Disruptive Medicine ETF (NASDAQ:FMED) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 9,896 shares of the company’s stock, valued at approximately $282,000. Citadel Advisors LLC owned about 0.62% of Fidelity Disruptive Medicine ETF at the end of the most recent reporting period.

Fidelity Disruptive Medicine ETF Stock Performance

Shares of NASDAQ:FMED opened at $31.67 on Friday. The business’s 50 day simple moving average is $30.97 and its two-hundred day simple moving average is $27.68. The firm has a market cap of $50.67 million, a P/E ratio of 41.33 and a beta of 0.77. Fidelity Disruptive Medicine ETF has a 52-week low of $23.48 and a 52-week high of $32.89.

Fidelity Disruptive Medicine ETF Company Profile

The Fidelity Disruptive Medicine ETF (FMED) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that invests in companies involved in disruptive innovation in Health Care. The fund invests in securities of domestic and foreign issuers FMED was launched on Apr 16, 2020 and is managed by Fidelity.